Chairs: TBC, TBC

ME02.1 Surveillance guidelines in paediatric and adult NF1 patients
Amedeo Azizi, Austria

ME02.2 Treatment of NF1 associated glioma
TBC, -

ME02.3 Treatment of plexiform neurofibroma
Said Farschtschi, Germany

ME02.4 Transition in neuro-oncology: How to transfer survivors with childhood NF1 associated glioma
TBC, -

Chairs: TBC, TBC

ME03.1 Neuro-Oncology Journal
Susan Chang, United States

ME03.2 Neuro-Oncology Advances Journal
Gelareh Zadeh, Canada

ME03.3 Neuro-Oncology Practice Journal
Martin Taphoorn, Netherlands

ME03.4 Neuro-Oncology Pediatrics
Sabine Mueller, United States

Chairs: TBC, TBC

OS03.1 Microglia/macrophage interactions in H3K27-altered glioma
Florent Ginhoux, France

OS03.2 What we learned from single-cell proteomics and transcriptomics on patient biopsies and mouse models
Bozena Kaminska, Poland

OS03.3 Good and bad neigborhoods in gliomas
Mario Suva, United States

OS03.4 Drivers of heteroenity in glioma
TBC, -

Chairs: TBC, TBC

JS01.1 Impact of cancer on the stress axis
Jeremy Borniger, United States

JS01.2 The role of the Brain-body axis in cancer cachexia
Thales Papagiannakopoulos, United States

JS01.3 Brain Cancer Ecosystems: A Dynamic Interplay Across Scales
Johanna Joyce, Switzerland

JS01.4 The impact of cancer on behaviour
Anastasia Maria Zavitsanou, United States

Chairs: TBC, TBC

JS02.1 Fluorescence-guidance and photodynamic therapy – new developments
Jane Skjoth Rasmussen, Denmark

JS02.2 Oncolytic virus
Marta Alonso, Spain

JS02.3 RT Dose Escalation in Glioblastoma: Lessons Learned from an International Multicenter Randomized Phase III Trial
Frank Giordano, Germany

JS02.4 Blood-brain barrier opening with ultrasound to enhance drug delivery to brain tumors - lessons learned
TBC, -

Michael Platten, Germany
President EANO

Giuseppe Minniti, Italy
President EANO Meeting 2026, Chair EANO Scientific Committee

Chairs: Gaetano Gargiulo, Estela Pineda

OS04.1 Neuronal degeneration and innate immunity during tumor initiation
Simona Parrinello, United Kingdom

OS04.2 Pericytes orchestrate and the tumor-suppressive microenvironment
Kristian Pietras, Sweden

OS04.3 TBC
TBC, -

OS04.4 Metabolomic responses of tumor ecosystem as adaptation to tumor progression, invasion and response to surgery
Thomas Daubon, France

Chairs: TBC, TBC

PD01.1 How to build resilience in a challenging work environment
Asgeir Jakola, Sweden

PD01.2 Parenting and care work as an academic researcher
Mariella Filbin, United States

PD01.3 Asking for what you need: How to set boundaries and ask for resources as a physician-scientist
Marjolein Geurts, Netherlands

PD01.4 Soft skills for hard realities: Managing politics in academic medicine
Anna Berghoff, Austria

Chairs: TBC, TBC

OS05.1 Managing behavioral disturbances in subjects with gliomas: bridging oncology and mental health care.
Alessio Simonetti, Italy

OS05.2 Cognitive Change in the First Year After Treatment for IDH-Mutant Gliomas
Isabelle Ryden, Sweden

OS05.3 Health-related quality of life in people diagnosed with diffuse low-grade glioma
Amelie Darlix, France

Chairs: TBC, TBC

PD02.1 Clinic
TBC, -

PD02.2 Research
TBC, -

Chairs: TBC, TBC

JS03.1 Biology Mismatch: What We Still Don’t Understand About GBM - A critical overview of the biological barriers that continue to undermine therapeutic progress in glioblastoma. Topics include extreme cellular and molecular heterogeneity, clonal evolution, tumor–microenvironment interactions, and the limitations of our understanding of treatment resistance.
Anna Golebiewska, Luxembourg

JS03.2 The role of neurosurgery in clinical trials: Merging Clinical Endpoints with Translational Discovery
Johnny Duerinck, Belgium

JS03.3 Trial Design Pitfalls: How Our Studies Were Set Up to Fail
Michael Weller, Switzerland

JS03.4 EORTC 2013 - GLIO-RARE
Maximilian Mair, Austria

JS03.5 EORTC 2227 - LEGATO
Tomas Kazda, Czech Republic

JS03.6 EORTC 2334 - LUMEN
Emeline Tabouret, France

JS03.7 EORTC 2427 - VIGOR
Marta Padovan, Italy